{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:01:54Z","timestamp":1790870514250,"version":"4.1.0"},"reference-count":38,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education Malaysia under the Fundamental Research Grant Scheme","doi-asserted-by":"publisher","award":["FRGS\/1\/2021\/SKK0\/UNISZA\/02\/5"],"award-info":[{"award-number":["FRGS\/1\/2021\/SKK0\/UNISZA\/02\/5"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Horizon Europe Guarantee Extension, UltiMalVax","award":["10079577"],"award-info":[{"award-number":["10079577"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: R21\/Matrix-M is a pre-erythrocytic malaria vaccine supported by a growing body of field-efficacy, immunogenicity, safety, controlled-challenge, and implementation evidence. We synthesized the contemporary human evidence and quantified protection against naturally acquired clinical malaria. Methods: This systematic review and meta-analysis was conducted and reported in accordance with PRISMA 2020. PubMed, Scopus, Embase, Web of Science, and Cochrane CENTRAL were searched for studies published from January 2021 to February 2026. The review was not prospectively registered, and no separate protocol was prepared. Eleven studies were retained for the systematic review. The primary quantitative synthesis pooled 12-month Cox proportional-hazards estimates for the first episode of clinical malaria from two independent randomized field trials using generic inverse variance methods. Robustness was examined using a fixed-effect model, a sensitivity analysis that disaggregated the phase III seasonal and standard\/perennial transmission strata, and a phase III-only analysis. Booster follow-up and controlled human malaria infection (CHMI) studies were summarized descriptively to avoid double counting and mixing of incompatible endpoints. Results: The primary trial-level meta-analysis yielded a pooled hazard ratio (HR) of 0.265 (95% CI 0.235\u20130.299), equivalent to vaccine efficacy (VE) of 73.5% (95% CI 70.1\u201376.5%), with no detected heterogeneity (I2 = 0%; Q = 0.67, p = 0.41; tau2 = 0). Disaggregating the phase III transmission strata produced a similar random-effects estimate (HR 0.270, 95% CI 0.223\u20130.326; VE 73.0%, 95% CI 67.4\u201377.7%; I2 = 53.8%). The fixed-effect estimate was HR 0.270 (95% CI 0.240\u20130.304), and the phase III-only sensitivity analysis remained strongly protective (HR 0.281, 95% CI 0.220\u20130.357; VE 71.9%). Booster follow-up supported maintained protection, including approximately 80% efficacy during the 12 months after boosting with the 50-microgram Matrix-M regimen. Across the broader evidence base, the vaccine was generally well tolerated and elicited strong anti-CSP\/anti-NANP antibody responses. Conclusions: R21\/Matrix-M provides substantial protection against naturally acquired clinical malaria, and the central efficacy estimate is robust to alternative analytic specifications. The quantitative evidence base remains small, however, and longer-term effectiveness, severe-malaria protection, booster timing, and post-deployment safety require continued evaluation.<\/jats:p>","DOI":"10.3390\/vaccines14090824","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:35:28Z","timestamp":1790868928000},"page":"824","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Response of R21\/Matrix-M in Malaria Vaccine: A Systematic Review and Meta-Analysis of Clinical Trials"],"prefix":"10.3390","volume":"14","author":[{"given":"Aneeq Ur","family":"Rehman","sequence":"first","affiliation":[{"name":"School of Biomedical Sciences, Faculty of Health Sciences, Universiti Sultan Zainal Abidin, Kuala Nerus 21300, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victory","family":"Nnaemeka","sequence":"additional","affiliation":[{"name":"The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4091-0610","authenticated-orcid":false,"given":"Muhammad Hassan","family":"Nasir","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universiti Sultan Zainal Abidin, Kuala Terengganu 20400, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurul Alia","family":"Azizan","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, Faculty of Health Sciences, Universiti Sultan Zainal Abidin, Kuala Nerus 21300, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9259-7339","authenticated-orcid":false,"given":"Ahmed M.","family":"Salman","sequence":"additional","affiliation":[{"name":"The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2020-900X","authenticated-orcid":false,"given":"Ahmad Syibli","family":"Othman","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, Faculty of Health Sciences, Universiti Sultan Zainal Abidin, Kuala Nerus 21300, Malaysia"},{"name":"The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e40241","DOI":"10.1097\/MD.0000000000040241","article-title":"Malaria pervasiveness in Sub-Saharan Africa: Overcoming the scuffle","volume":"103","author":"Alum","year":"2024","journal-title":"Medicine"},{"key":"ref_2","unstructured":"World Health Organization (2025). Malaria Surveillance, Monitoring and Evaluation: A Reference Manual, World Health Organization."},{"key":"ref_3","unstructured":"World Health Organization (2025). TDR Annual Report 2024: Building Local Research Solutions to Improve Global Health, World Health Organization."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12936-023-04811-z","article-title":"Estimated distribution of malaria cases among children in sub-Saharan Africa by specified age categories using data from the Global Burden of Diseases 2019","volume":"22","author":"Oshagbemi","year":"2023","journal-title":"Malar. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12936-025-05368-9","article-title":"Urban malaria in sub-Saharan Africa: A scoping review of epidemiologic studies","volume":"24","author":"Merga","year":"2025","journal-title":"Malar. J."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Turan, G., Boggio, M.J., Othman, A.S., Nnaemeka, V., Hill, A.V.S., and Salman, A.M. (2026). Recent Advances, Bottlenecks, and Future Directions in Plasmodium falciparum Vaccine Development. Vaccines, 14.","DOI":"10.3390\/vaccines14030277"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/14760584.2023.2292204","article-title":"Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond","volume":"23","author":"Hammershaimb","year":"2024","journal-title":"Expert Rev. Vaccines"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3389\/fimmu.2020.01597","article-title":"The Impact of Malaria Parasites on Dendritic Cell-T Cell Interaction","volume":"11","author":"Osii","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Dzi, K.T.J. (2023). Issues related to the approval of the R21\/Matrix-M malaria vaccine for use in Nigeria and Ghana. Front. Public Health, 11.","DOI":"10.3389\/fpubh.2023.1237011"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"taad140","DOI":"10.1093\/jtm\/taad140","article-title":"R21\/Matrix-M\u2122 malaria vaccine: A new tool to achieve WHOs goal to eliminate malaria in 30 countries by 2030?","volume":"30","author":"Genton","year":"2023","journal-title":"J. Travel Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e20241908","DOI":"10.1084\/jem.20241908","article-title":"Repertoire, function, and structure of serological antibodies induced by the R21\/Matrix-M malaria vaccine","volume":"222","author":"McDaniel","year":"2025","journal-title":"J. Exp. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.pedhc.2024.05.010","article-title":"Examining Vaccine Hesitancy Among Ghanaian Parents for the R21\/Matrix-M Malaria Vaccine","volume":"38","author":"Ghazy","year":"2024","journal-title":"J. Pediatr. Health Care"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1473-3099(24)00010-0","article-title":"R21\/Matrix-M malaria vaccine: A vital tool in the arsenal against malaria, not a silver bullet","volume":"24","author":"Ngou","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12936-024-04921-2","article-title":"Hesitancy towards R21\/Matrix-M malaria vaccine among Ghanaian parents and attitudes towards immunizing non-eligible children: A cross-sectional survey","volume":"23","author":"Hussein","year":"2024","journal-title":"Malar. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e1797","DOI":"10.1002\/hsr2.1797","article-title":"Unlocking the potential of novel RTS, S\/AS01, and R21\/Matrix-M\u2122 malaria vaccines in African nations","volume":"7","author":"Oduoye","year":"2024","journal-title":"Health Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1473-3099(23)00816-2","article-title":"The public health impact and cost-effectiveness of the R21\/Matrix-M malaria vaccine: A mathematical modelling study","volume":"24","author":"Schmit","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/S0140-6736(21)01065-5","article-title":"R21\/Matrix-M: A second malaria vaccine?","volume":"397","author":"Moorthy","year":"2021","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1097\/MS9.0000000000001648","article-title":"Breaking the malaria barrier: The WHO-approved R21\/Matrix-M vaccine and its global impact\u2014An editorial","volume":"86","author":"Verma","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: A phase 1\/2b randomised controlled trial","volume":"22","author":"Datoo","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","article-title":"Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: A multicentre, double-blind, randomised, phase 3 trial","volume":"403","author":"Datoo","year":"2024","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: A randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100867","DOI":"10.1016\/S2666-5247(24)00083-1","article-title":"R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18\u201345 years: An open-label, partially blinded, phase 1-2a controlled human malaria infection study","volume":"6","author":"Venkatraman","year":"2025","journal-title":"Lancet Microbe"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41541-024-00920-1","article-title":"A randomised trial of malaria vaccine R21\/Matrix-M\u2122 with and without antimalarial drugs in Thai adults","volume":"9","author":"Hanboonkunupakarn","year":"2024","journal-title":"npj Vaccines"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.12688\/wellcomeopenres.19795.1","article-title":"Safety and immunogenicity of varied doses of R21\/Matrix-M\u2122 vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya","volume":"8","author":"Sang","year":"2023","journal-title":"Wellcome Open Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"100868","DOI":"10.1016\/S2666-5247(24)00084-3","article-title":"Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: Two phase 1, first-in-human trials","volume":"6","author":"Venkatraman","year":"2025","journal-title":"Lancet Microbe"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41591-025-04107-6","article-title":"Malaria vaccine protection against intradermal or venous parasites: A randomized phase 2b human challenge trial","volume":"32","author":"Kapulu","year":"2026","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1620366","DOI":"10.3389\/fimmu.2025.1620366","article-title":"Vaccine-induced responses to R21\/Matrix-M\u2014An analysis of samples from a phase 1b age de-escalation, dose-escalation trial","volume":"16","author":"Bundi","year":"2025","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e015524","DOI":"10.1136\/bmjgh-2024-015524","article-title":"Acceptability of the R21\/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context","volume":"10","author":"Diawara","year":"2025","journal-title":"BMJ Glob. Health"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"46621","DOI":"10.1038\/srep46621","article-title":"Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine","volume":"7","author":"Collins","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2189885","DOI":"10.1080\/21645515.2023.2189885","article-title":"The Matrix-M\u2122 adjuvant: A critical component of vaccines for the 21st century","volume":"19","author":"Stertman","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/postmj\/qgae086","article-title":"A new era in malaria prevention: A comparative look at RTS,S\/AS01 and R21\/Matrix-M vaccines","volume":"100","year":"2024","journal-title":"Postgrad. Med. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0140-6736(23)02716-2","article-title":"R21\/Matrix-M vaccine: Optimising supply, maximising impact","volume":"403","author":"Nnaji","year":"2024","journal-title":"Lancet"},{"key":"ref_35","unstructured":"World Health Organization (2024). WHO Malaria Policy Advisory Group (MPAG) Meeting Report, 30 October\u20131 November 2023, World Health Organization."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1001\/jama.2024.12589","article-title":"Malaria Rapid Tests, Febrile Illness Management, and Child Mortality Across Sub-Saharan African Countries","volume":"332","author":"Zhang","year":"2024","journal-title":"JAMA"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Bennett, J.W., Yadava, A., Tosh, D., Sattabongkot, J., Komisar, J., Ware, L.A., McCarthy, W.F., Cowden, J.J., Regules, J., and Spring, M.D. (2016). Phase 1\/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001\/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004423"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"939291","DOI":"10.3389\/fepid.2022.939291","article-title":"Genomic approaches for monitoring transmission dynamics of malaria: A case for malaria molecular surveillance in Sub-Saharan Africa","volume":"2","author":"Mensah","year":"2022","journal-title":"Front. Epidemiol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/824\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:36:12Z","timestamp":1790868972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["vaccines14090824"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14090824","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]}}}